ICAR Sinonasal Tumors, Part 2: Malignant Neoplasms and Quality of Life (2023 AMW)
2023 AAO-HNSF Annual Meeting & OTO Experience
Management of sinonasal malignancies may be challenging due to the complex anatomy of the sinonasal region and proximity to critical neurovascular structures. Furthermore, due to the rarity of these tumor types, treatment guidelines and recommendations may be difficult to define. As such, a multidisciplinary, international consortium of experts has convened to develop an international consensus statement on sinonasal tumors (ICSNT). There are 30 topics in the consensus statement, which were developed by an editorial team, and expert authors from all over the world were invited to perform systematic or literature reviews. In addition, the statement includes an Executive Summary and detailed description of the methods, which followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Evidence-based reviews (EBR) or evidence-based reviews with recommendations (EBRR) were developed and underwent iterative reviews by two associate editors until consensus was achieved. Topics included epidemiology, diagnostic workup, imaging, pathology, surgical approaches and complications, margin analysis, adjuvant therapies, prognosis, quality of life, and surveillance. This two-part panel will be comprised of the editors and associate editors of this consensus statement, and highlights from the statement will be discussed. We will focus on state-of-the-art management of sinonasal malignancies based on a histopathology-driven approach, as well as quality of life, surveillance, morbidity following treatment, and survivorship. Summaries and recommendations, when appropriate, for specific tumor types will be addressed. These guidelines will be highly relevant for otolaryngologists as they manage patients with sinonasal tumors. Finally, research and future directions for treatment of malignant sinonasal tumors will be discussed.
Credits
CME:1.0, MOC:1.0